Skip to main content

Table 1 Associations between CCND1 amplification status, cyclin D1 protein expression and clinicopathological variables in all patients

From: Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

All patients Cyclin D1 cytoplasmic intensity (negative/low, intermediate, high) Cyclin D1 nuclear intensity (negative/low, intermediate, high) Cyclin D1 nuclear fraction (< 1%,1 to 9%, 10 to 32%, 33 to 67%, > 67%) Tumour grade (well, moderate, poor) Tumour sizea (mm) Nodal status (negative, 1 to 3, > 3) Ki67a
CCND1 amplification       
   Nonamplified 12%, 52%, 36% 40%, 36%, 24% 10%, 24%, 27%, 24%, 15% 23%, 61%, 16% 18.0 70%, 23%, 7% 4.0
   Amplified 6%, 48%, 46% 9%, 35%, 56% 0%, 6%, 18%, 32%, 44% 9%, 62%, 29% 19.0 64%, 26%, 10% 7.5
  Armitage (P = 0.063) Armitage (P < 0.001) Armitage (P < 0.001) Armitage (P < 0.001) Wilcoxon (P = 0.083) Armitage (P = 0.341) Wilcoxon (P < 0.001)
Cyclin D1 cytoplasmic intensity       
   Negative/low   74%, 16%, 10% 23%, 33%, 26%, 11%, 4% 26%, 59%, 15% 17.5 68%, 24%, 8% 3.2
   Intermediate   40%, 36%, 24% 10%, 24%, 27%, 25%, 14% 17%, 63%, 20% 19.0 64%, 34%, 2% 4.6
   High   20%, 43%, 37% 3%, 16%, 25%, 28%, 28% 23%, 61%, 16% 17.0 74%, 20%, 6% 5.6
   Goodman = 0.44 (P < 0.001) Goodman = 0.39 (P < 0.001) Goodman = -0.06 (P = 0.238) Cuzick trend (P = 0.010) Goodman = -0.12 (P = 0.031) Cuzick trend (P = 0.021)
Cyclin D1 nuclear intensity       
   Negative/low    23%, 33%, 26%, 11%, 4% 24%, 62%, 14% 18.0 67%, 25%, 8% 2.9
   Intermediate    1%, 12%, 41%, 36%, 10% 18%, 65%, 17% 18.0 68%, 25%, 7% 4.8
   High    0%, 1%, 7%, 37%, 55% 17%, 59%, 24% 17.5 71%, 22%, 7% 6.3
    Goodman = 0.88 (P < 0.001) Goodman = 0.16 (P < 0.001) Cuzick trend (P = 0.553) Goodman = -0.05 (P = 0.327) Cuzick trend (P < 0.001)
Cyclin D1 nuclear fraction       
   < 1%     18%, 68%, 14% 20.0 2%, 29%, 9% 2.8
   1 to 9%     23%, 62%, 15% 18.0 68%, 25%, 7% 2.7
   10 to 32%     24%, 59%, 17% 18.0 71%, 25%, 4% 4.4
   33 to 67%     20%, 59%, 21% 18.0 70%, 21%, 9% 4.9
   > 67%     12%, 68%, 20% 16.0 68%, 24%, 8% 5.9
     Cuzick trend (P = 0.005) Spearman ρ = -0.04 (P = 0.162) Cuzick trend (P = 0.694) Spearman ρ = 0.22 (P < 0.001
  1. Tests used: Armitage's trend test, Wilcoxon test, Goodman's test, Spearman correlation test and Cuzick test. aMedian value for each category.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us